Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NMPA Approval

Rifaximin Tablets

Approval Number

国药准字HJ20181212

CompanyALFASIGMA SPA

Registration Date

June 7, 2023

Previous Approval Numbers

H20181212

Drug Information

Generic Name

利福昔明片

Trade Name

昔服申

Dosage Form

片剂

Strength

0.2g

Drug Type

化学药品

Registration Date

June 7, 2023

Expiry Date

June 6, 2028

Company Information

Applicant Company

Company NameALFASIGMA SPA

Company Address

VIA RAGAZZI DEL＇99,5-40133 BOLOGNA, Italy

Manufacturing Company

Company NameALFASIGMA SPA

Company Address

VIA ENRICO FERMI,1-65020 ALANNO (PE), Italy

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy

利福昔明片 - NMPA 批准文号 | MedPath